Cleveland Clinic Cancer Advances
Trailblazing Urothelial Cancer Treatments: Enfortumab Vedotin & Pembrolizumab
02 May 2024
Shilpa Gupta, MD, Director of the Genitourinary Oncology Program at Cleveland Clinic Cancer Institute, provides an overview of the clinical trial of enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. Listen as Dr. Gupta talks about the exciting results of the trial, which showed that the combination therapy was effective for both cisplatin-eligible and cisplatin-ineligible patients. She also highlights the future studies that are being conducted to explore the use of the therapy in the neoadjuvant setting.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View
Reducing Burnout and Boosting Revenue in ASCs
10 Dec 2025
Becker’s Healthcare -- Spine and Orthopedic Podcast